Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma

Eur J Haematol. 2004 May;72(5):377-8. doi: 10.1111/j.1600-0609.2004.00232.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CD8 Antigens / analysis
  • Cyclophosphamide / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Doxorubicin / administration & dosage
  • Female
  • Gemcitabine
  • Humans
  • Immunophenotyping
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Pentostatin / administration & dosage
  • Prednisone / administration & dosage
  • Remission Induction
  • Salvage Therapy
  • Skin Neoplasms / drug therapy*
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • CD8 Antigens
  • Organoplatinum Compounds
  • Oxaliplatin
  • Deoxycytidine
  • Pentostatin
  • Alemtuzumab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
  • Gemcitabine

Supplementary concepts

  • CHOP protocol